Mn Services Vermogensbeheer B.V. Acquires 2,500 Shares of DexCom, Inc. (NASDAQ:DXCM)

Mn Services Vermogensbeheer B.V. increased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 1.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 150,600 shares of the medical device company’s stock after buying an additional 2,500 shares during the quarter. Mn Services Vermogensbeheer B.V.’s holdings in DexCom were worth $11,712,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of DXCM. Forvis Mazars Wealth Advisors LLC raised its position in DexCom by 0.7% in the fourth quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company’s stock valued at $1,359,000 after purchasing an additional 118 shares during the last quarter. Principal Securities Inc. raised its position in DexCom by 3.4% in the fourth quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company’s stock valued at $316,000 after purchasing an additional 135 shares during the last quarter. Crossmark Global Holdings Inc. raised its position in DexCom by 1.0% in the third quarter. Crossmark Global Holdings Inc. now owns 18,778 shares of the medical device company’s stock valued at $1,259,000 after purchasing an additional 182 shares during the last quarter. GPS Wealth Strategies Group LLC raised its position in DexCom by 13.2% in the fourth quarter. GPS Wealth Strategies Group LLC now owns 1,587 shares of the medical device company’s stock valued at $123,000 after purchasing an additional 185 shares during the last quarter. Finally, Peterson Wealth Services raised its position in DexCom by 7.1% in the fourth quarter. Peterson Wealth Services now owns 3,030 shares of the medical device company’s stock valued at $236,000 after purchasing an additional 201 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, CEO Kevin R. Sayer sold 33,359 shares of the firm’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $2,899,230.69. Following the transaction, the chief executive officer now owns 319,037 shares in the company, valued at $27,727,505.67. This trade represents a 9.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Jacob Steven Leach sold 2,634 shares of the firm’s stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the transaction, the chief operating officer now owns 268,644 shares in the company, valued at $23,347,850.04. This represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 38,083 shares of company stock worth $3,309,794. Corporate insiders own 0.30% of the company’s stock.

DexCom Trading Up 0.6 %

NASDAQ DXCM opened at $88.37 on Friday. The business has a 50 day simple moving average of $84.69 and a 200 day simple moving average of $76.67. The stock has a market capitalization of $34.53 billion, a P/E ratio of 61.80, a P/E/G ratio of 2.30 and a beta of 1.14. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Research analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have commented on the company. Citigroup increased their target price on DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Morgan Stanley increased their target price on DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research report on Friday, February 14th. Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and increased their price target for the company from $85.00 to $115.00 in a research note on Monday, February 3rd. Finally, Wells Fargo & Company increased their price target on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Four investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $99.06.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.